AI-based Infection Control Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The aI-based infection control systems market size is expected to grow from USD 0.86 billion in 2025 to USD 1.02 billion in 2026 and is forecast to reach USD 2.48 billion by 2031 at 19.47% CAGR over 2026-2031. This report is Segmented by Offering (Software, Hardware, Services), Deployment Model (Cloud-Based, On-Premise, Hybrid), End User (Acute Care Hospitals, Long-Term Care Facilities, Ambulatory Surgical Centers, Clinics and Specialty Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global AI-based Infection Control Systems Market Trends and Insights

Rising HAI and AMR Burden

The clinical case for the AI-based infection control systems market starts with a burden that manual surveillance has not contained. A 2024 systematic review found that infection preventionists spend nearly half of their work hours on surveillance-related tasks, while HAI incidence in ICUs ranged from 17% in neonatal units to 68% in adult critical care units globally. The same review noted that hospital-acquired bloodstream infections carry a 10% to 20% mortality rate and add nearly USD 40,000 in cost per surviving patient, which keeps the financial case for earlier detection very clear. Published studies also show that AI-enabled surveillance can reduce HAI incidence from 1.31% to 0.58% and cut manual chart review workloads by 83.9%, which gives hospital buyers a direct link between automation and labor relief. The pressure rises further as antimicrobial resistance remains a central policy focus, with the UN target tied to the 2019 baseline of 4.95 million deaths and global antibiotic consumption expected to rise by more than 30% by 2030. That combination keeps predictive surveillance and stewardship tools near the center of adoption decisions across the AI-based infection control systems market.

Tightening Infection Reporting Mandates

Regulation is turning procurement into a compliance decision for many hospitals in the AI-based infection control systems market. Since January 2024, the CMS Medicare Promoting Interoperability Program has required eligible hospitals and critical access hospitals to submit antimicrobial use and resistance data to the CDC’s NHSN. By 2024, 73% of hospitals were meeting the requirement through a mix of automated and manual methods, but 57% identified AUR reporting as their most difficult public health reporting task, which shows where manual workflows still break down. CMS also tied fiscal year 2026 payment exposure to HAI-related performance under the HAC Reduction Program, including CLABSI, CAUTI, MRSA bacteremia, CDI, and surgical site infection measures. The fiscal year 2026 proposed IPPS rule moves further toward digital quality measurement using FHIR standards, which will increase the value of platforms that can capture, normalize, and transmit infection data in real time.

High Deployment and Validation Costs

Cost remains a real barrier in the AI-based infection control systems market because implementation goes well beyond software licensing. Hospitals still need data integration work, workflow redesign, user training, and local validation before infection surveillance models can be trusted in daily practice. The burden is heavier in systems with limited digital maturity, and Germany’s DigitalRadar 2024 average of 42 out of 100 shows that even funded hospital systems can still lack the foundation needed for easy AI deployment. Validation also remains a live concern because independent reviews have shown that AI performance can weaken outside controlled deployment settings, which forces providers to budget for monitoring and retraining after go-live. These factors slow decisions in mid-sized hospitals, rural facilities, and lower-resource settings where infection control needs are high, but capital and technical staffing remain limited.

Other drivers and restraints analyzed in the detailed report include:

• EHR and Clinical Data Interoperability Expansion
• Growth in Cloud-Based Surveillance Adoption
• Data Privacy and Cybersecurity Concerns

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software held 67.42% of the AI-based infection control systems market share in 2025, which reflects the scalability of analytics and surveillance platforms compared with hardware-led deployments. This lead also mirrors how hospitals buy, because most providers prefer a software layer that can sit on top of existing EHR, laboratory, and pharmacy systems instead of replacing physical infrastructure. Products such as Wolters Kluwer’s Sentri7 show why software remains entrenched, with the platform ranking first in KLAS for infection control and monitoring in 2026 and reinforcing the value of usable surveillance workflows for clinical teams. The software-heavy mix also fits a budget pattern where infection prevention teams continue to prioritize automation tools that reduce manual review, reporting burden, and repetitive follow-up work.

Services in the AI-based infection control systems industry are projected to expand at a 21.9% CAGR through 2031, which makes them the fastest-rising part of the service mix. The growth reflects the practical challenge of integrating AI into heterogeneous hospital environments where validation, tuning, and workflow adaptation continue well after the initial installation. Managed support is becoming more important because providers need help maintaining model performance, aligning alerts to local clinical practice, and keeping reporting outputs consistent with evolving compliance rules. Hardware remains a supporting layer in the AI-based infection control systems industry, but product refreshes such as Vitalacy’s Gen5 wearable and BioVigil’s AccuWash rollout show that badges, sink beacons, and sensing devices still matter where hand hygiene and staff behavior monitoring are core use cases.

Complete Report Scope:

• By Offering
  • Software
  • Hardware
  • Services
• By Deployment Model
  • Cloud-Based
  • On-Premise
  • Hybrid
• By End User
  • Acute Care Hospitals
  • Long-Term Care Facilities
  • Ambulatory Surgical Centers
  • Clinics and Specialty Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.23% of the AI-based infection control systems market share in 2025, which reflects strong regulatory infrastructure, a large NHSN-reporting hospital base, and a vendor ecosystem centered in the United States. The region’s demand accelerated after CMS made AUR reporting mandatory from January 2024 for eligible hospitals and critical access hospitals under the Promoting Interoperability Program. By 2024, 73% of hospitals were already submitting AUR data, but 57% still identified that requirement as their most difficult reporting task, which directly supports demand for automated surveillance platforms. North America also benefits from a dense field of established vendors and reference sites that make procurement less experimental than in many other regions. Platforms such as Sentri7 and Premier’s clinical surveillance tools continue to benefit from this environment because hospitals want measurable workflow savings and easier public health reporting.

Europe remains an important part of the AI-based infection control systems market because funding support, public digital health policy, and research networks are moving in the same direction, even if implementation is uneven across the region. Germany’s Krankenhauszukunftsgesetz created a EUR 50 billion fund, equivalent to USD 53.5 billion, for hospital transformation, yet the 2024 DigitalRadar average of 42 out of 100 still shows that digital readiness remains incomplete. The RISK PRINCIPE consortium and the Charité surveillance work show that interoperable data pipelines can already produce hospital-onset bacteremia monitoring at scale, which gives Europe a solid research-to-deployment bridge. France’s AP-HP also reported nearly 300 internal AI initiatives by mid-2025, while the EU AI Act and the European Health Data Space are likely to concentrate growth around vendors that can meet strict certification and data governance requirements.

Asia-Pacific AI-based infection control systems market size is projected to expand at 23.5% CAGR through 2031, making it the fastest-growing regional block. Growth in this region reflects more than headline HAI burden, because governments and health systems are also building stronger infectious disease intelligence and hospital data infrastructure. Japan’s establishment of the Japan Institute for Health Security in April 2025 supports that direction by creating a more centralized infectious disease intelligence framework, while hospital-level AI readiness continues to improve in parallel. India and other emerging Asian markets add a different demand profile, where ICU infection rates remain high and lighter surveillance tools can be attractive when full EHR integration is not yet available. The Middle East and Africa and South America remain smaller parts of the AI-based infection control systems market, but growth should follow hospital digitization, GCC healthcare infrastructure investment, and gradual modernization of public networks in countries such as Brazil.

List of Companies Covered in this Report:

• Ascom
• BioVigil Hygiene Technologies LLC
• Beckton Dickinson
• Baxter
• Cognosos, Inc.
• Epic Systems
• Ecolab
• GOJO Industries, Inc.
• Inovalon Holdings, Inc.
• Kontakt.io, Inc.
• Oracle
• Sonitor Technologies
• Softgent SRL
• SwipeSense, Inc.
• Premier, Inc.
• PatientVoice AI, Inc.
• Vitalacy, Inc.
• Wolters Kluwer

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support